Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery

Monocentric Pilot Study of Effect of Perioperative Hemodynamic Optimization on the Immune Function Parameters of Peripheral Blood Monocytes After Cardiac Surgery

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01184430

Acronym

Algebra

Enrollment

Registered

2010-08-19

Start date

2013-08-31

Completion date

2014-12-31

Last updated

2013-08-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative Outcome, Postoperative Wound Infection

Keywords

advanced hemodynamic monitoring, goal-directed therapy, cardiac surgery, hemodynamic monitoring

Brief summary

Cardiac surgery patients have a high risk to suffer from postoperative infections. Some studies have shown, that humoral and cellular factors are associated with perioperative immunodysfunction and can increase the risk of postoperative infections. Monocytes in the blood and, especially alveolar macrophages are important for an adequate host defence. In studies the investigators have shown that hemodynamic parameters have a significant influence on the probability to develop postoperative infections. The aim of the study is to investigate, whether cardiac surgery patients have an altered immune function after surgery that is predictive for the latter development of subsequent infections and whether they benefit from a goal-directed volume and hemodynamic therapy.

Interventions

DEVICEPulse contour cardiac output device

Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* elective cardiac surgery patient undergoing cardiopulmonary bypass * signed informed consent

Exclusion criteria

* pregnant or breast feeding women * Age \<18 years * pulmonary disease with an oxygenation index \<300mmHg * liver disease (\>Child B) * HIV-Infection * Therapy with corticosteroids * Condition after transplantation * preexisting infection before operation

Design outcomes

Primary

Measure	Time frame
HLA-DR Expression on monocytes after surgery	24 hours

Secondary

Measure	Time frame
ICU stay	24 hours

Countries

Germany

Contacts

Primary ContactMichael Sander, MD

Michael.Sander@charite.de+49 30 450 531

Backup ContactKatharina Berger, MD

Katharina.Berger@charite.de+49 30 450 531

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026